Is there still a role for tremelimumab in the treatment of cancer?

Paolo A. Ascierto


It was surprising to first learn, at the 2008 ASCO annual meeting, that the phase III trial of tremelimumab for the treatment of advanced melanoma did not have a positive result with regard to its primary endpoint. After very promising data in phase II studies, the difference in overall survival (OS) between the tremelimumab and standard of care control (temozolomide or dacarbazine) arms was not statistically significant (11.8 versus 10.7 months). Despite this, at that point in time, an OS of 11.8 months for advanced melanoma patients seemed exceptional, given the historical median OS of 6-8 months for these patients (1).